References

1. 1.
   SUN H， SAEEDI P， KARURANGA S， et al. IDF diabetes atlas： Global， regional and country-level diabetes prevalence estimates for 2021 and projections for 2045［J］. Diabetes Res Clin Pract， 2022，183：109-119.
2. 2.
   TEO Z L， THAM Y C， YU M， et al. Global prevalence of diabetic retinopathy and projection of burden through 2045： Systematic review and Meta-analysis［J］.Ophthalmology，2021，128（11）：1580-1591.
3. 3.
   APTE R S， CHEN D S， FERRARA N. VEGF in signaling and disease：Beyond discovery and development［J］. Cell，2019，176（6）：1248-1264.
4. 4.
   HUANG H， HE J，JOHNSON D， et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition［J］. Diabetes，2015，64：200-212.
5. 5.
   HE M X，XIE J，MENG Q L.Research status and progress of hypoxia-inducible factor on the regulation of diabetic retinopathy［J］.Chin J Ocul Fund Dis，2021，37（8）：661-664.
6. 6.
   MELINCOVICI C S， BOSCA A B， SUSMAN S， et al. Vascular endothelial growth factor （VEGF）-key factor in normal and pathological angiogenesis［J］. Rom J Morphol Embryol， 2018，59（2）：455-467.
7. 7.
   GROSS J G，GLASSMAN A R，et al.Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy：A randomized clinical trial［J］. JAMA， 2015，314（20）：2137-2146.
8. 8.
   ULUDAG G， HASSAN M，MATSUMIYA W，et al. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy：What we have learned and what should we learn further？［J］.Expert Opin Biol Ther，2022，22（10）：1275-1291.
9. 9.
   DING J F，TU J.Chinese medicine treats diabetic microangiopathy：A review［J］.Chin J Exp Tradit Med Form，2023，29（6）：260-267.
10. 10.
    ZHOU Y K，LI Q，ZHANG H R，et al.Small molecules of traditional Chinese medicine inhibiting neovascularization：Research progress on mechanism［J］.Acad J Naval Med Univ，2023，44（5）：616-621.
11. 11.
    SUN Y X，ZUO T，ZHANG Z Q，et al.Clinical observation of using Huayu Mingmu compound combnied with Xueshuantong injection by iontophoresis in the treatment of diabetic retinopathy with deficiency of both Qi and Yin［J］.J Tianjin Univ Tradit Chin Med，2021，40（6）：744-747.
12. 12.
    MA X Q，ZUO T，MA X D，et al.Study on the effect and mechanism of Huayu Mingmu recipe-containing serum on angiogenesis in high glucose-induced functional disorder model of HRMECs［J］.Tradit Chin Drug Res Clin Pharmacol，2023，34（12）：1668-1677.
13. 13.
    HE C Q，YANG T Y，WANG L Y，et al.Establishment and evaluation of rat model of type 2 diabetes［J］.Chin J Proc Engin，2015，15（3）：501-505.
14. 14.
    ZHU X Y，LIU Q，BAI H L，et al.Establishment of type 2 diabetes retinopathy rat model［J］.Lab Animal Sci，2022，39（1）：28-33.
15. 15.
    PAN L，ZHOU S P，GUO Y R，et al.Experimental study on morphological changes of retinal microvessels in diabetes［J］.Chin J Ophthalmol，2004，40（6）：58-60.
16. 16.
    SONG E，DONG Y，SHI B，et al.Evaluation of experimental animal model of diabetic retinopathy induced by STZ rat［J］.Chin J Ophthalmol，2004，40（2）：124-127.
17. 17.
    PANG D B，FU L J，LIU X Z.An investigation of the pathology of the retinal microvascular network in rats with diabetes induced by streptozotocin［J］.Chin J Optom Ophthalmol Visual Sci，2005，7（1）：47-49.
18. 18.
    XU S Y.Pharmacological experimental methodology［M］.BeiJing：People's Medical Publishing House，2002：238.
19. 19.
    XING P P，WANG X.Research progress on traditional Chinese medicine treatment of diabetic retinopathy［J］.China J Tradit Chin Med Pharm，2014，29（3）：813-815.
20. 20.
    JIA H Y，FENG Z H，FENG W S，et al.Traditional Chinese medicine monomers in treatment of diabetic retinopathy by regulating PI3K/Akt signaling pathway：A review［J］.Chin J Exp Tradit Med Form，2023，29（12）：265-273.
21. 21.
    LIU S Z，YANG H D，ZHANG H Z，et al.Relationship between signaling pathway and diabetic retinopathy and intervention of traditional Chinese medicine：A review［J］.Chin J Exp Tradit Med Form，2023，29（22）：265-275.
22. 22.
    LI X M，YU Y X，HU G L，et al.Research advance in the regulatory role of PI3K/Akt signaling pathway in the occurrence and development of eye diseases［J］.Recent Adv Ophthalmol，2021，41（6）：588-592.
23. 23.
    NAKAHARA T， MORITA A， YAGASAKI R， et al.Mammalian target of rapamycin （mTOR） as a potential therapeutic target in pathological ocular angiogenesis［J］. Biol Pharm Bull，2017，40（12）：2045-2049.
24. 24.
    WEI J， JIANG H， GAO H， et al. Blocking mammalian target of rapamycin （mTOR） attenuates HIF-1α pathways engaged-vascular endothelial growth factor （VEGF） in diabetic retinopathy［J］. Cell Physiol Biochem， 2016，40（6）：1570-1577.
25. 25.
    KIDA T，OKU H，HORIE T，et al. Implication of VEGF and aquaporin 4 mediating müller cell swelling to diabetic retinal edema［J］.Graefes Arch Clin Exp Ophthalmol， 2017， 255：1149‑1157.
26. 26.
    ZENG M，SHEN J，LIU Y，et al.The HIF-1 antagonist acriflavine：Visualization in retina and suppression of ocular neovascularization［J］.J Mol Med （Berl），2017，95（4）：417-429.
27. 27.
    BREIER G. Functions of the VEGF/VEGF receptor system in the vascular system［J］.Semin Thromb Hemost， 2000，26（5）：553-559.
28. 28.
    TAKAHASHI H，SHIBUYA M.The vascular endothelial growth factor （VEGF）/VEGF receptor system and its role under physiological and pathological conditions［J］.Clin Sci （Lond），2005，109（3）：227-241.
29. 29.
    PARK S W，YUN J H，KIM J H，et al.Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy［J］. Diabetes， 2014，63（9）：3057-3068.
30. 30.
    MENDEN H，WELAK S，COSSETTE S，et al. Lipopolysaccharide （LPS）-mediated angiopoietin-2-dependent autocrine angiogenesis is regulated by NADPH oxidase 2 （Nox2） in human pulmonary microvascular endothelial cells［J］.J Biol Chem， 2015，290（9）：5449-5461.
31. 31.
    LIU Q Y，SHAO Y，LI X R.The present research and progress of angiopoietin in diabetic retinopathy［J］.Chin J Ocul Fund Dis，2022，38（11）：944-948.
32. 32.
    YANG Y.The anti-inflammatory of salidroside in theinhibition of microglia of DR through PI3K/Akt pathway［D］.Jinzhou：Jinzhou Medical University，2021.
33. 33.
    YANG D，BAO Y L，ZHANG S L.et al.Blueberry anthocyanins on oxidative damage in diabetic retinopathy model rats：Repair effect and mechanism analysis［J］.Hebei Med J，2023，45（1）：44-47.
34. 34.
    LI N，LAI J，SHU Q Y，et al .Study on action mechanism of Huoxue Tongluo prescription regulating PI3K/Akt signaling pathway to improve diabetic retinopathy in rats［J］.New Chin Med，2022，54（24）：1-6.
35. 35.
    LIU X Q，TAN H Y，PENG J，et al.Mechanism of Sanxue Mingmu tablet in preventing and treating proliferative vitreoretinopathy based on MAPK and PI3K/Akt signal pathways［J］.China J Tradit Chin Med Pharm，2020，35（5）：2355-2361.
36. 36.
    LI H，LUO X X，FENG Y P，et al.Effects of a traditional Chinese patent medicine for PI3K/Akt pro-survival signal channel in diabetic retinopathy rat［J］.Intern Eye Sci，2016，16（12）：2195-2199.
37. 37.
    FANG Y C.The study of Mingmu Xiaomeng tablet regulates autophagy through PI3K/Akt/mTOR pathway in diabetic retinopathy［D］.Guangzhou：Guangzhou University of Chinese Medicine，2020.
38. 38.
    RAN Z L.The study of curcumin regulates the PI3K/Akt/mTOR pathway in diabetic retinopathy［D］.Shijiazhuang：Hebei Medical University，2018.
39. 39.
    YAN Y T，WANG X L，GU Y Y，et al.Crocin inhibits hypoxia-induced angiogenesis of retinal pigment epithelial cells via HIF-1α/VEGF pathway［J］.Chin J Immunol，2019，35（16）：1957-1961.
40. 40.
    WEI F Y，WANG J，LIU Q Z，et al.Effect of Danshen（Salvia miltiorrhiza） extracts on prevention and treatment of diabetic retinopathy in rat model based on HIF-1α/VEGF signaling pathway［J］.Chin Arc Tradit Chin Med，2023，41（10）：187-191，292-294.
41. 41.
    DENG Z D，HUANG Y Z，PAN L S，et al.Effect of flavonoid from diospyros kaki leaf on expressions of CTGF，VEGF，HIF-1α in retina of KKAy mice［J］.Chin J Exp Tradit Med Form，2017，23（2）：115-119.
42. 42.
    LI C，WANG A L，ZHAO Z Q，et al.Protective effect of astragaloside Ⅳ on the retina of type 2 diabetic rats［J］.Pharmacol Clin Chin Mater Med，2024，40（5）：63-67.
43. 43.
    CHEN S L，KANG Z F，CHU W L，et al.Mechanism of curcumin inhibiting choroidal neovascularization in brown Norway rat［J］.Int Eye Sci，2023，23（4）：537-545.